Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone replacement in men with late-onset hypogonadism and MASLD
jRCTs031260069Recruiting
- Sponsor
- Japan Society for the Promotion of Science
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of testosterone enanthate and testosterone in late-onset hypogonadism (LOH) and metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Japan Society for the Promotion of Science. Primary endpoint: Change in hepatic fat content by MRI-PDFF. Started Jun 2026; status: recruiting.
02
Drugs
testosterone enanthatetestosterone
03
Conditions
late-onset hypogonadism (LOH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on jRCTs031260069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260069.